# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# SCHEDULE 14A

(Rule 14a-101)

# INFORMATION REQUIRED IN PROXY STATEMENT

# SCHEDULE 14A INFORMATION


Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Reg	gistrant 🗆
Filed by a Party	other than the Registrant ⊠
Check the appro	priate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
$\boxtimes$	Definitive Additional Materials
	Soliciting Material Under § 240.14a-12
	MIND MEDICINE (MINDMED) INC.
	(Name of Registrant as Specified In Its Charter)
	(Name of Registrate as Specified in its Charlet)
	FCM MM HOLDINGS, LLC
	JAKE S. FREEMAN
	CHAD BOULANGER
	DR. SCOTT FREEMAN
	DR. FARZIN FARZANEH
	VIVEK JAIN
	ALEXANDER J. WODKA
	(Name of Persons(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filir	ng Fee (Check all boxes that apply):
$\boxtimes$	No fee required
	Fee paid previously with preliminary materials
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

FCM MM Holdings, LLC, a Wyoming limited liability company, together with the other participants in its solicitation (collectively, "FCM"), has filed a definitive proxy statement and accompanying **BLUE** proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2023 annual general meeting of shareholders of Mind Medicine (MindMed) Inc., a British Columbia corporation.

Item 1: On June 6, 2023, FCM posted the following materials on various social media platforms:









Consumer Health & Wellness

Last updated: 3m ago &

# MindMed activist slams proxy advisor as blind to patient safety



FCM MM Holdings LLC is an activist investment group with a 3.5% stake in Mind Medicine Inc., a psychedelic pharmaceutical company.

# What Happened


FCM defended its board nominees and strategic plan in a statement today attacking the proxy advisor Institutional Shareholder Services. ISS has recommended that MindMed shareholders vote for all six of the company's own director candidates, rather than FCM's nominees.


## What to Know

FCM, led by MindMed's co-founder and former chief medical officer, is urging shareholders that board changes are necessary for the company to safely and efficiently bring novel mental health treatments to market. The activist group has criticized current management for the dosing of trial patients at levels deemed unsafe by the FDA, among other reasons.

ISS' recommendation "ignore(s) the Board's failed clinical strategy that continues to destroy shareholder value" and "turns a blind eye to ... actions that we believe jeopardized patient safety," the group writes. FCM argues that without new leadership MindMed will run out of money in 2024 and inevitably dilute shareholders' outstanding stock to fill the holes.

Read FCM's response to ISS' recommendation here. This is not a solicitation.





Promoted










# \$MNMD troop.com/posts/rfqda878ho?...







Item 2: On June 6, 2023, FCM posted a video on Facebook, Instagram, TikTok and YouTube concerning the Company. A transcript of the video is pasted below.

#### Dr. Scott Freeman's Plans For Mind Medicine, \$MNMD

This is not solicitation.

This company could have the first FDA approved psychedelic medicine available to the public, but a group of shareholders are not happy with the current leadership.

Mind Medicine is a medical research company that develops psychedelic therapies to address addiction and mental illness.

The company's stock drastically fell, and a group of shareholders are dissatisfied with overall performance.

Now, the activist group, FCM, who has over a 5.6% ownership of the company, has launched a battle to take over Mind Medicine.

FCM is claiming that the current leadership of Mind Medicine is hurting the chances of taking these treatments for anxiety and addiction to-market.

They're arguing that the leader of FCM, Dr. Scott Freeman, and co-founder and former CMO, should be elected onto the board of directors, as well as proposing a slate of new directors.

FCM argues the current leadership caused over a billion dollars in shareholder value lost as the stock plunged 95%.

To fix this, FCM wants to reduce executive pay, because Mind Med leadership pay was tripled while the stock value was declining.

What do you think of FCM's involvement at Mind Medicine?

For information on how to vote your \$MNMD shares, call Okapi Partners: (855) 305-0856 (toll free), or email info@okapipartners.com

Item 3: On June 5, 2023, FCM sent the following materials via e-mail to certain shareholders of the Company:



# Shareholder Alert: MindMed Proxy Vote

Presented by troop

Participate in the upcoming MindMed (MNMD) annual meeting.

The following message is from Troop, a community platform for shareholder activism:

#### Quick context:

- The FDA has <u>signaled support</u> for the use of psychedelic substances to treat generalized anxiety disorders.
- Activist investors are pushing for leadership changes at MindMed that they say will better position the company for this opportunity, and rein in executive compensation.

#### Why it matters:

- Activist investors (FCM holdings) believe MindMed's Board requires deeper experience in the clinical trial process for complex drugs in order to improve the company's speed-to-market and avail the opportunities that come with the ability to treat generalized anxiety disorders.
  - The proposal includes bringing back MindMed's original co-founder,
    Dr. Scott Freeman.
- MindMed's current Board is advocating for keeping the 6 current board members as is.

## What it means for you:

- As a shareholder in MNMD, you can participate in the upcoming proxy vote and have a say in the future direction of the company.
- Vote "FOR" the four FCM Holdings nominees, or with the current Board, on your proxy ballot.

#### How to vote:

## The deadline to vote digitally is Weds., June 14th.

You should have received an email and/or physical letter from ProxyVote with your unique control number. If you're having trouble finding this, search your inbox for id@proxyvote.com.

#### Online

- 1. Locate the control number on your Voting Instruction Form.
- If your control number is 16 digits: log on to www.proxyvote.com, OR if your control number is 12 digits: log on to www.proxypush.com
- 3. Enter your control number to vote by Weds. 6/14

#### Telephone

- 1. Locate the control number on your Voting Instruction Form.
- If your control number is 16 digits, dial 1-800-454-8683 toll-free, OR if your control number is 12 digits, dial toll-free 1-866-586-3109.
- 3. Enter your control number on your phone keypad to vote.

#### Mai

Mark, sign, and date your proxy card or voting instruction form and return it in the postage-paid envelope provided. Paper ballots must be received by Monday, 6/12.

Learn more

#### Activist investing for all

Troop is a community app for shareholders to unite and change companies, like MindMed, for good. Discover campaigns, launch new ones, and stay updated on shareholder votes and tips that matter in your portfolio.

Join Troop

The above content reflects sponsored content and is for general informational purposes only. It is not a solicitation. It is not intended to constitute investment advice or any other kind of professional advice and should not be relied upon as such. Before taking action based on any such information, we encourage you to consult with the appropriate professionals. We do not endorse any third parties referenced within the article. Market and economic views are subject to change without notice and may be untimely when presented here. Do not infer or assume that any securities, sectors or markets described in this article were or will be profitable. Past performance is no guarantee of future results. There is a possibility of loss. Historical or